Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

In a meta-analysis, Saw and coworkers compared trials on retina detachment surgery and found no clear evidence in favor for any technique. It seemed that too many aspects are important for the ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment. The best-in-class gene therapy product candidate ...

ATSN-201 leverages AAV.SPR, the company's novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal ...

Durham-based Atsena Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for ATSN-201, its gene therapy product for the ...

In this Q&A, John D. Gelles, OD, and Steven Greenstein, MD, chat about what inspired them to launch the symposium, what makes ...

So the plan of action was to fix the retina detachment. “They had to wait for the swelling in my eye to go down before they would operate. When it did, the doctor said the detachment was too ...

alpha \text{s}$ ) distributions for white process representation of retinal optical coherence tomography (OCT) images. According to validation by statistical tests, this model well justifies the heavy ...